Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 5/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.31 |
| ▸ | TYMS | P04818 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8662388 | 0.78 | — | — | |
| SCHEMBL25520154 | 0.73 | IGF2R (0.35) | — | |
| SCHEMBL25083776 | 0.73 | FBP1 (0.43) | — | |
| SCHEMBL24894612 | 0.72 | THRB (0.33) | — | |
| SCHEMBL30186693 | 0.72 | IGF2R (0.43) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL24894020 | 0.72 | IGF2R (0.43) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL25083656 | 0.70 | NPC1 (0.33) | — | |
| SCHEMBL25084276 | 0.70 | — | — | |
| SCHEMBL25084279 | 0.70 | — | — | |
| SCHEMBL24894242 | 0.69 | THRB (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | M6PR, ASGR1, IGF2R | GRIN2D 3781/4885GRIN3B 1649/4885GRIN1 3223/4885 |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, ASGR1, FCGR3B | GRIN2D 4416/4885GRIN3B 1562/4885GRIN1 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.